BBA
SPRY icon

Baker Bros. Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Baker Bros. Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,006,451
Closed -$11M – 89
2023
Q4 		$11M Hold
2,006,451
– – 0.13% 44
2023
Q3 		$7.58M Hold
2,006,451
– – 0.04% 55
2023
Q2 		$13.4M Hold
2,006,451
– – 0.08% 50
2023
Q1 		$13.1M Hold
2,006,451
– – 0.07% 44
2022
Q4 		$17.1M Buy
+2,006,451
New +$13M 0.1% 47
2021
Q3 		– Sell
-238,095
Closed -$7.36M – 128
2021
Q2 		$7.36M Hold
238,095
– – 0.03% 85
2021
Q1 		$10.4M Hold
238,095
– – 0.05% 73
2020
Q4 		$11M Buy
+238,095
New +$7.95M 0.04% 72

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's SPRY Position: Q1 2024 in Review

Baker Bros. Advisors sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 2,006,451 shares — an estimated $11M sold.

Baker Bros. Advisors first reported a position in SPRY in Q4 2020 and held it in 8 quarters. The position peaked at $17.1M in Q4 2022. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Baker Bros. Advisors reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,006,451 ARS Pharmaceuticals shares in Q1 2024, an estimated $11M.
  • Baker Bros. Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Baker Bros. Advisors's ARS Pharmaceuticals position peaked at $17.1M in Q4 2022.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.